There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIO – Research Report) and BioLife Solutions (BLFS – Research Report) with bullish sentiments.
BioLife Solutions (BLFS)
Maxim Group analyst Jason McCarthy maintained a Buy rating on BioLife Solutions yesterday. The company’s shares closed last Thursday at $22.28, close to its 52-week high of $24.50.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $24.13, which is a 5.4% upside from current levels. In a report issued on May 13, Benchmark Co. also upgraded the stock to Buy with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FBIO:
- Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
- Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
- Fortress Biotech announces first patient dosed in Phase 2 study of triplex
- Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
